WO1990001550A1 - Translation de haut rendement de messages polycistroniques dans des cellules eucariotiques - Google Patents

Translation de haut rendement de messages polycistroniques dans des cellules eucariotiques Download PDF

Info

Publication number
WO1990001550A1
WO1990001550A1 PCT/US1989/003228 US8903228W WO9001550A1 WO 1990001550 A1 WO1990001550 A1 WO 1990001550A1 US 8903228 W US8903228 W US 8903228W WO 9001550 A1 WO9001550 A1 WO 9001550A1
Authority
WO
WIPO (PCT)
Prior art keywords
leader
plasmid
transcription unit
protein
expression
Prior art date
Application number
PCT/US1989/003228
Other languages
English (en)
Inventor
Kathleen L. Berkner
Original Assignee
Zymogenetics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics, Inc. filed Critical Zymogenetics, Inc.
Publication of WO1990001550A1 publication Critical patent/WO1990001550A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor

Definitions

  • the present invention relates to the expression of proteins in general and, more specifically, to the high efficiency translation of polycistronic messages in cultured cells derived from multicellular organisms.
  • glycoproteins in mammalian cells has the advantage of providing proteins which contain natural glycosylation.
  • Mammalian-produced glycoproteins contain outer chain carbohydrate moieties which are markedly different from the outer chain carbohydrate moieties present on glycoproteins produced from lower eucaryotes.
  • mammalian cells as hosts for the production of secreted proteins has the significant advantage over secretion from lower eucaryotes in that mammalian cells have a secretory system that readily recognizes and properly processes secretion-directed proteins, which is not necessarily true for lower eucaryotes.
  • Methods for expression of cloned DNA sequences in a variety of higher eucaryotic cell lines are known in the art. Cloned DNA sequences may be introduced into mammalian cells using procedures widely reported in the literature (for review see Thilly, ed. , Mammalian Cell
  • cloned DNA sequences In mammalian cells, the expression of cloned DNA sequences has been increased by inserting coding sequences for proteins of interest into expression units containing transcription control sequences, which include promoter sequences, enhancer sequences, leader sequences, splice signals and polyadenylation signals. Identification of clones containing transfected DNA sequences is facilitated by co-introducing a selectable marker with an expression unit. Expression levels may be optimized, for example, through amplification using selection for an amplifiable selectable marker. However, co-amplification of the expression unit is not guaranteed in every clone, particularly when the selectable marker is introduced as an independent DNA sequence.
  • cloned DNA sequences into an expression unit does not guarantee efficient gene expression when the expression unit is introduced into the host cell.
  • Low expression levels of cloned coding sequences may result from inefficient transcription or translation of the coding sequence, unstable messenger RNA (mRNA) sequences, instability of the protein production, or the presence of toxic sequences in an expression vector.
  • the recombinant protein may be improperly, inadequately or inefficiently post- transcriptionally processed by the host cell.
  • Efficient expression of coding sequences in eucaryotic hosts may also require the expression of associated proteins which are required for the processing, stabilization or modification of the protein to achieve biological activity.
  • Optimal expression of biologically active recombinant proteins may also be dependant upon the presence of translation and/or transcription factors.
  • proteins may be present in a host cell at such low levels that efficient expression of recombinant proteins is limited.
  • proteins that require specific post-translational modification include certain coagulation factors, which require gamma-carboxylation of specific glutamic acid residues for biological activity and may also require the conversion of specific aspartic acid residues to beta-hydroxy aspartic acid for biological activity.
  • proteins which are present as multimers in their active forms are composed of disparate subunits.
  • Certain multimeric proteins, such as insulin are encoded within the same cistron and are post-translationally processed into multimers containing heterologous polypeptides.
  • Other multimeric proteins are encoded by DNA sequences which are not located within the same cistron. Examples of proteins of this type include coagulation factor XIII, which is a tetramer made of a- and b chains, PDGF, which is present as an A-B dimer, immunoglobulins, hemoglobin and the major histocompatibility antigens.
  • DNA sequences which function to enhance or enable expression of cloned DNA sequences.
  • Other DNA sequences include coding sequences for processing enzymes, transcription factors, translation factors, stabilizing proteins and protease inhibitors.
  • Optimal expression of a recombinant protein in a host cell may require the co-introduction of many coding sequences.
  • Methods for introducing multiple expression units into host cells include co-transfection with multiple expression vectors (Dubois et al., Proc. Natl Acad. Sci. USA 77:4549-4553, 1980; Subramani and Berg, Cell .16:777-785, 1979), transfection with vectors containing more than one expression unit (Stafford and Queen, Nature 306:77-79, 1980; Ochi et al., Proc. Natl. Acad. Sci. USA 8j0: 6351-6355, 1983; Kadesch and Berg, Moi. Cell. Biol. 6_:2593-2601, 1986) and transfection with vectors containing polycistronic transcription units (Peabody and Berg, Moi. Cell. Biol.
  • the choice of an optimal selectable marker system is further limited by the few selectable markers which have been shown to co-amplify associated DNA sequences. Selectable markers are reviewed by Thilly (ibid.).
  • the introduction of multiple expression vectors is also limited by the number of useful cell lines which are multiply deficient in activities complemented by selectable markers or are multiply sensitive to compounds for which selectable markers provide resistance and which are also known to provide the post-translational processing required by many recombinant proteins.
  • the identification of a cell line which appears to be a suitable host for particular selection and expression systems does not guarantee that the cell line will be amenable to selection for or amplification of the marker.
  • the probability of co-introduction of multiple expression vectors into a host cell decreases with an increase in the number of DNA sequences one seeks to co- introduce.
  • Co-amplification of the expression units in the selected clones is also an unpredictable event.
  • the probability of co-amplification of all co-transfected DNA sequences to an equal amplified gene dosage is reduced with the number of DNA sequences involved.
  • the present invention discloses a method for enhancing the expression of proteins in cultured cells derived from a multicellular organism.
  • the method generally comprises: (a) introducing into the cultured host cell a polycistronic transcription unit of the formula:
  • P-C-JL (HEL-C n ) m , wherein P is a transcriptional promoter, C is a DNA sequence encoding a protein, HEL is a high efficiency leader, n is a positive integer greater than zero, m is an integer from 1 to 8, inclusive; and (b) growing the cultured host cell in an appropriate medium.
  • the cultured host cell is a mammalian host cell.
  • the polycistronic transcription unit may further include a leader positioned downstream of the promoter and upstream of C _ .
  • viral leaders particularly high efficiency viral leaders.
  • C- ⁇ and C n may be subunits of a ulti- subunit protein, such as factor XIII, platelet derived growth factor, immunoglobulins or histocompatibility antigens.
  • Polycistronic transcription units for use within the method described above as well as cultured cells derived from a multicellular organism into which such a polycistronic transcription unit has been introduced are also disclosed.
  • Figure 1 illustrates the construction of pBoel360, a plasmid containing a polycistronic transcription unit in the vector pML-1.
  • Symbols used are Ad5 ori, the 0-1 map units of adenovirus 5; E, SV40 enhancer sequence; Ad2 MLP, the major late promoter from adenovirus 2; Ll-3, the adenovirus 2 tripartite leader sequence; 5'ss, 5' splice signal; 3'ss, 3' splice
  • pA the late polyadenylation signal from SV40.
  • Figure 2 illustrates the construction of plasmid pTP/Cla.
  • Figure 3 illustrates the production of dicistronic mRNA.
  • a SI analysis of mRNA produced by BHK cells transfected with plasmid pD5CAT-DHFR r (arrows) . Numbers on the right refer to size markers, b, diagrams of the dicistronic expression unit, dicistronic mRNA, and probe. The dotted line indicates mRNA spliced out in some transcripts.
  • Figure 4 illustrates the construction of plasmid pTP/F9/Cla.
  • Figure 5 illustrates the construction of plasmid pFVII-P-BiP. Best Mode for Carrying Out the Invention
  • Cistron A DNA sequence encoding a protein or polypeptide. This DNA sequence may be in the form of a gene, cDNA, or synthetic DNA fragment, or a clone thereof.
  • Polycistron A DNA sequence containing at least two cistrons in which the cistrons are separated by at least the termination codon of the upstream cistron and the translation start codon of the downstream cistron.
  • a polycistron does not contain a functional transcriptional promoter between the cistrons.
  • Intercistronic region The DNA sequence between the translation termination codon of an upstream cistron and the translation initiation codon of a downstream cistron in a polycistron.
  • Polycistronic transcription unit A DNA sequence containing a polycistron operably linked to a transcriptional promoter. Transcription of the polycistron results in a single mRNA containing sequences corresponding to the component cistrons.
  • Leader sequence A 5' untranslated sequence which effects efficient translation of transcribed messages.
  • Splice signal A sequence showing consensus with 5' or 3' sequences as reported by Mount (Nuc. Acids Res. 10.:459-472, 1982) that has been functionally shown to participate in a mRNA splicing event (i.e., scission and ligation reactions resulting in the excision of intervening sequences)
  • the present invention discloses novel DNA constructs useful for enhancing the level of expression of proteins from downstream cistrons in polycistronic transcription units.
  • These novel DNA constructs contain polycistrons in which DNA sequences encoding proteins of interest are joined in tandem, being separated by a DNA sequence encoding a leader sequence.
  • These polycistrons are joined to potent transcriptional and translational signals in suitable expression vectors and are introduced into cultured cells derived from multicellular organisms. Surprisingly, these constructs have been found to produce an increase in expression of the downstream cistron.
  • Polycistrons of the present invention may be generated by joining coding sequences with a leader sequence such that the leader sequence is between the coding sequences.
  • Each coding sequence will have associated with it translational start and stop signals in correct reading frame.
  • the leader sequence is inserted into the intercistronic region using restriction endonuclease digestion and ligation.
  • Preferred leader sequences are viral leader sequences, which include the adenovirus first leader and the adenovirus Ll-IX leader (Berkner and Sharp, Nuc. Acids Res. 11:841-857, 1985), the SV40 leader and the parvovirus leader.
  • a particularly preferred leader sequence is the high efficiency viral leader, adenovirus tripartite leader (Ll-3) .
  • Suitable cellular leaders include the ovalbumin leader. It may be advantageous to append the leader sequence directly to the translation initiation sequence. In one embodiment of the present invention, the leader sequence becomes appended to the translation initiation codon following a splicing event from splice signals within the transcription unit. Within another embodiment, the leader may be joined to the translation initiation sequence by in vitro mutagenesis. Cultured cells derived from multicellular organisms, such as mammalian cells, infected with a recombinant virus containing this potent translation signal in the intercistronic region of a polycistronic transcription unit have been found to express the downstream cistron at levels comparable to those obtained using monocistronic expression units.
  • the downstream cistron is not detectably expressed in infected cells.
  • Cells transfected with plasmids carrying polycistronic expression units including an intercistronic leader exhibit at least a 20-fold increase in protein expression from the second cistron when compared to cells containing a comparable plasmid lacking the intercistronic signal.
  • leader sequences may be identified by the insertion of 5' noncoding sequences into a viral or a plasmid test system. Such systems have been utilized to study adenovirus leader sequences (see, for example, Berkner and Sharp, Nuc. Acids Res. 13:841-857, 1985 and Kaufman, Proc. Natl. Acad. Sci. USA 82:689-693, 1985) . Briefly, a potential leader sequence (a 5 ** noncoding sequence) of interest is inserted into an expression unit comprising at least a transcriptional promoter operatively linked to a marker coding sequence, such as .DHFR, such that the potential leader sequence is inserted immediately 5' to the translation initiation site of the marker coding sequence.
  • a potential leader sequence a 5 ** noncoding sequence
  • the marker coding sequence is preferably one for which an assay exists. Marker coding sequences include DHFR and hepatitis B surface antigen (Davis et al., Proc. Natl. Acad. Sci. USA 2.7560-7564, 1985).
  • Vectors suitable for transfecting mammalian cells include derivatives of pBR322 (Bolivar et al., Gene 2 . :95-113, 1977), such as pML-1 (Lusky and Botchan, Nature 293:79- 81, 1981) , and derivatives of the pUC (Messing, Meth. Enzymol. 101:20-79- 1983) vectors.
  • Vectors suitable for use in transfecting other host cells are described by, for example, Kretsovali et al. (ibid.), Miyajima et al.
  • the resultant expression vectors are transfected into host cells and the expression of the marker is compared to the marker expressed by cells transfected with the expression vector without the leader sequence. At least a five ⁇ fold increase in marker expression in cells transfected with an expression vector containing a leader sequence over cells transfected with an expression vector without a leader sequence identifies a suitable leader sequence. A greater than five-fold increase in expression with an expression vector carrying the leader sequence identifies a high efficiency leader. Leader sequences may be tested in a viral system, such as adenovirus, by constructing recombinant viruses with the plasmid expression units described above.
  • the resultant recombinant viruses are used to infect host cells and the levels of marker expression are measured. At least a five-fold increase in marker expression in cells infected with an expression unit containing a leader sequence over cells infected with an expression unit without a leader sequence identifies a suitable leader sequence. A greater than five-fold increase in marker expression with an expression unit carrying a leader sequence identifies a high efficiency leader sequence.
  • suitable leaders are used in constructing polycistronic expression vectors as described below. Such vectors will contain additional genetic elements which facilitate the high level expression of the protein(s) of interest.
  • the polycistronic expression units of the present invention are inserted into vectors.
  • Suitable vectors include recombinant plasmids as described above.
  • Recombinant virus vectors include the SV40 viral vectors and adenovirus vectors (for review see, Thilly, ibid.).
  • a particularly preferred vector is a recombinant adenovirus (hereinafter ⁇ • Ad") vector. Expression of cDNAs using Ad vectors has been achieved, for example by Berkner et al. (Nuc. Acids. Res. 11:841-857, 1985).
  • Recombinant adenovirus vectors containing polycistronic transcription units provide the advantage of introducing the transcription unit into virtually every cell of any tissue or cell line. This may be particularly advantageous if the polycistronic transcription unit is to be used in gene therapy.
  • a transcrip ⁇ tional promoter is positioned upstream of the translation initiation signal of the first cistron.
  • suitable promoters include the mouse metallothionein (MT-1) promoter (Palmiter et al., Science 222:809-814, 1983), the SV40 late promoter (Piatak et al., J. Virol 4_8:503-520, 1983), the SV40 early promoter (Benoist and Chambon, Nature 290:304-310, 1981), and the cytomegalovirus (CMV) promoter.
  • Viral promoters are preferred due to their efficiency in directing transcription.
  • a particularly preferred promoter is the major late promoter from adenovirus, although any efficient promoter can be utilized in the disclosed methodology. It may be advantageous to include, in an expression unit, a leader sequence located downstream of the promoter and upstream of the first cistron.
  • Preferred leader sequences include the adenovirus first leader, the adenovirus Ll-IX leader and the ovalbumin leader.
  • a particularly preferred leader sequence is the adenovirus tripartite leader. Suitable leader sequences may be identified by screening methods described above.
  • the expression unit may contain splice signals composed of a 5 ' splice signal and a 3' splice signal.
  • the 5' splice signal may be associated with a leader sequence such as any of those mentioned above.
  • the 5' splice signal is a sequence associated with the adenovirus L3 leader.
  • the 3 ' splice signal may be any one of a number of splice signals (for review see Mount, ibid.) such as the rabbit beta-globin 3' splice signal (Ruskin et al.. Cell 18:317-331, 1984).
  • a particularly preferred 3 ' splice signal is from the variable region of an immunoglobulin gene.
  • a polyadenylation signal located downstream from the DNA sequences comprising the polycistron.
  • Viral polyadenylation signals such as the early or late polyadenylation signals from SV40 or the polyadenylation signal from the adenovirus Elb region, are particularly preferred.
  • Polyadenylation signals may also be supplied by the coding sequences present in the polycistron.
  • Preferred vectors may also include enhancer sequences, such as the SV40 enhancer, preferably located upstream of the promoter.
  • a selectable marker be introduced into the cells along with the polycistronic transcription unit.
  • Selectable markers include the neomycin resistance gene, the hygromycin gene, the Ecogpt gene, the thymidine kinase gene, the adenine phophoribosyltransferase gene, the hypoxanthine phosphoribosyltransferase gene, and multiple drug resistance factors (Roninson et al., Proc. Natl. Acad. Sci USA 81:4538-4542, 1986; Ueda et al. , J. Biol. Chem. 2_62 . :505-508, 1987).
  • the selectable marker will be an amplifiable selectable marker.
  • a preferred amplifiable selectable marker is the DHFR gene.
  • a particularly preferred amplifiable selectable marker is the DHFR r cDNA (Simonsen and Levinson, Proc. Natl. Acad. Sci. USA 80:2495-2499, 1983) . Selectable markers are reviewed by Thilly (ibid.) and the choice of selectable markers is well within the level of ordinary skill in the art.
  • Selectable markers may be introduced into the cell as separate DNA sequences at the same time as the polycistronic transcription unit, as cistrons in the polycistronic trancription unit, or as independent expression units on the same vector. It may be particularly advantageous to place an amplifiable selectable marker as the terminal cistron in. a polycistronic transcription unit such that the penultimate cistron and the selectable marker are not separated by a leader sequence. A selectable marker so placed is translated at a reduced efficiency and forces the amplification of the selectable marker and its associated DNA sequences to compensate for the selective conditions.
  • Polycistronic transcription units as described within the present invention have wide application in the production of recombinant proteins in eucaryotic cells. These applications include the use of polycistronic messages to produce commercial quantities of therapeutic and commercially important proteins or to be used in applications of gene therapy. Polycistronic messages may be adapted to encode proteins of interest and coding sequences which enhance or enable the expression of biologically active proteins of interest. Proteins which function to enhance or enable the expression of recombinant proteins include processing enzymes, protease inhibitors, stabilizing factors, transcription factors, translation factors and selectable markers.
  • polycistronic transcription units may be utilized in combination with an adenovirus vector system in gene therapy.
  • Gene therapy is the insertion into an organism of a DNA coding sequence which corrects a genetic defect in the host organism.
  • the only human tissues which have been used for gene transfer are bone marrow and skin cells.
  • Polycistronic transcription units may be constructed which allow efficient expression of proteins of interest in tissues where those proteins do not occur in nature.
  • Current studies on human gene therapy have concentrated on using human genes introduced into human cells by insertion into retroviruses.
  • adenovirus vectors may prove to be advantageous over retrovirus vectors for the introduction of genes for gene therapy.
  • Adenovirus is able to transform a variety of human and rodent cell lines to generate stable integrants and it has a proven ability to penetrate every cell during infection.
  • a highly infective, transforming, recombinant adenovirus vector may prove to be advantageous over retrovirus vectors for gene therapy.
  • DNA sequences encoding therapeutic and economically useful proteins which may be expressed in polycistronic transcription units include, but not are restricted to, those coding for blood coagulation factors, a variety of serine proteases, growth factors, protein C, protein S, tissue plasminogen activator, immunoglobulins, histocompatibility antigens, plasminogen, anti-inflammatory proteins, anticoagulants and analogs and derivatives of these proteins. Many of these proteins occur as multi-subunit proteins whose coding sequences are not located within the same cistron. Expression of multi-subunit proteins in mammalian cells requires the expression of coding sequences for all of the subunits.
  • Multi-subunit proteins include factor XIII, platelet-derived growth factor, immunoglobulins, the major histocompatability antigens and hemoglobin.
  • Examples of multi-subunit proteins which may require co-expression of component subunits within the same host cell are factor XIII and immunoglobulins.
  • Factor XIII is a tetramer composed of a 2 and b 2 dimers (Chung et al., J. Biol. Chem. 249:940- 950, 1974) . It has been shown that the b 2 dimer acts to stabilize the a 2 dimer.
  • Immunoglobulins are known to require expression of both heavy and light chains for secretion of functional immunoglobulins (Hickman and Kornfield, ibid; Kearney et al., ibid.; Hendershot et al. , ibid.) .
  • Polycistronic messages may also encode processing proteins which are required in enhanced levels to efficiently produce high levels of biologically active proteins.
  • Processing proteins include proteases which cleave a precursor protein at a particular site to provide the mature and/or active form of a protein or proprotein, or which cleave a single- chain protein to a multi-chain form.
  • Other examples of processing proteins are those which modify amino acids, such as gamma-carboxylase, an enzyme which modifies specific glutamic acid residues of certain coagulation factors and other calcium binding proteins; enzymes responsible for the conversion of aspartic acid to beta- hydroxy aspartic acid, a modification necessary for the biological activity of protein C; and enzymes responsible for hydroxylation of proline residues.
  • processing proteins include enzymes responsible for myristoylation, C-terminal amino acid removal, sulfation, C-terminal amidation and the addition of carbohydrate chains to glycoproteins.
  • a processing enzyme which is not naturally found in mammalian cells and may be incorporated into a polycistronic transcription unit is the J i. cerevisiae KEX2 gene product.
  • the KEX2 gene product is an endopeptidase which cleaves at Lys-Arg residues.
  • a KEX2 coding sequence and a protein C coding sequence are encoded in a polycistronic transcription unit.
  • the KEX2 gene product facilitates processing of the precursor form of protein C.
  • Polycistronic transcription units may also include coding sequences for stabilizing proteins.
  • Stabilizing proteins include protease inhibitors which block the proteolytic degradation of the protein of interest; proteins which bind to the protein of interest making it unavailable to degrading enzymes; proteins which bind to proteins as co-factors, or other molecules required by a protein; and proteins which inactivate co- factors.
  • An example of a coding sequence which functions to stabilize or facilitate activation of another protein in a polycistron is protein S. Protein S functions to bind to protein C and allows acceleration in the activation of protein C.
  • a protein C- protein S polycistron may improve expression of activated protein C.
  • An example of a stabilizing protein is von Willebrand factor (vWF) .
  • vWF von Willebrand factor
  • a polycistron which encodes both vWF and coagulation factor VIII will produce vWF, which functions to stabilize coagulation factor VIII and may increase the half life of the factor VIII in the extracellular medium.
  • Polycistronic transcription units may incorporate DNA sequences which encode transcription or translation factors (Dynan and Tijan, Nature 316:774- 777, 1985; Baeuerle and Baltimore, Cell 53:211-217, 1988; Hattman et al., Gene J55.:345-351, 1987; Kaufman et al., Moi. Cell. Biol. 7:3759-3766.
  • a polycistronic transcription unit comprising the coding region for spl linked to a gene or cDNA of interest which encodes or has been modified to encode spl recognition sequences may allow greater transcription of the coding sequence of interest. It may be advantageous to include sequences in polycistronic transcription units that encode proteins which facilitate the secretion of other proteins.
  • An example of a polycistronic transcription unit which encodes a secreted protein and a protein which may aid in the secretion of other proteins is one which contains factor VII and BiP coding sequences.
  • the immunoglobulin binding protein BiP is found in the lumen of the endoplasmic reticulum (ER) and has a C-terminal amino acid sequence of Lys-Asp-Glu-Leu (Munro and Pelham, Cell . 46:291-300, 1986).
  • Munro and Pelham ibid. note that the KDEL tetrapeptide may be part of a signal which causes retention of the proteins in the ER.
  • the secretion of factor VII which shares some homology with the C-terminal amino acid sequence of BiP, may be retarded due to the presence of a potential retention signal.
  • the co-expression of BiP, which is preferentially retained within the ER, with factor VII, may saturate the host ER retention system, thus allowing factor VII to be more efficiently secreted.
  • Expression vectors according to the present invention may be introduced into cultured cells by, for example, calcium phosphate-mediated transfection (Wigler et al., Cell 14.:724, 1975, Corsaro and Pearson, Somatic Cell Genetics 2:603, 1981; Graham and Van der Eb, Virol. 5_2.:456-467, 1973) or by electroporation (Neumann, EMBO -L.
  • Viral expression vectors may also be used to infect a host cell using methods described by, for example, Kaufman (Proc. Natl. Acad. Sci. USA 11:689-693, 1985) It may also be advantageous to add additional DNA, known as "carrier DNA,” to the mixture which is introduced into the cells.
  • Cells which can be grown in culture and express cloned DNA sequences include cells of mammals, insects (Miyajima et al., ibid.), amphibians (Wolf and Qui by, Science 144:1578, 1964 and Freed et al. , Biology of Amphibian Tumors, Mizell ed. , pp 101-111, Springer Verlag, 1969) , reptiles (Clark, J. Natl. Cancer Inst. 41:1097-1102, 1969; Clark, J. Natl. Cancer Inst. 4 .
  • mammalian cell lines for use in the present invention include the COS (ATCC CRL 1650), BHK (ATCC CCL 10), CHO and 293 (ATCC 1573) cell lines as well as derivatives and isolates of these cell lines, although it will be evident to those skilled in the art that other cell lines may be preferred for production of particular proteins. Mammalian tissue may also be suitable for use in the present invention.
  • a host cell line or tissue will be selected on the basis of its ability to produce the protein of interest at a high level and/or its suitability for use with a desirable selectable marker.
  • the present invention allows one to produce virtually any protein in practically any cell line which can be grown in vitro.
  • the cells are generally allowed to grow for a period of time, typically 1-2 days, to begin expressing the gene of interest.
  • Cells containing expression vectors according to the present invention may be grown in an appropriate medium.
  • Medium for facilitating growth of cultured eucaryotic cells contains a carbon source, amino acids and vitamins in a balanced salt solution supplemented with defined growth factors or serum.
  • Selection pressure is applied to select for the growth of cells which are expressing the selectable marker.
  • methotrexate selection for example, increasing the concentration of the drug in a stepwise manner allows selection for increased copy number of the cloned sequences, resulting in increased expression levels.
  • Clones of such cells may be screened for production of the protein of interest. Cells are grown and proteins are isolated from the cells by lysis. Useful screening methods include immunological assays and activity assays.
  • Methods for purification of recombinant proteins are generally known in the art. Where the protein is retained within the host cell, it will be necessary to first disrupt the cell and remove cell debris, preferably by centrifugation, to produce a cleared lysate. In the case of a secreted protein, the protein is purified directly from the culture medium. The cleared lysate or medium is fractionated by conventional protein purification methods. A multi-step process will generally be used. Typical procedures in this regard include precipitation (e-g- , with polyethylene glycol or ammonium sulfate) , ion exchange chromatography, affinity chromatography, preparative gel electrophoresis, high performance liquid chromatography, and fast pressure liquid chromatography. In some cases it is preferable .
  • precipitation e-g- , with polyethylene glycol or ammonium sulfate
  • affinity chromatography affinity chromatography
  • preparative gel electrophoresis high performance liquid chromatography
  • fast pressure liquid chromatography In some cases it is
  • Plasmid pD3 comprising the Ad5 ori, SV40 enhancer, Ad2 major late promoter, Ad2 tripartite leader, 5' and 3 splice signals, a DHFR cDNA, the SV40 polyadenylation signal and pML-1 vector sequences, was constructed to introduce a unique Bel I site 5" to the DHFR coding sequence.
  • the Pst I site immediately downstream from the DHFR coding sequence in pDHFRIII was converted to a Bel I site.
  • the adhesive ends of Pst I partially digested pDHFRIII were deleted using dCTP in the presence of T 4 DNA polymerase. The DNA was then ethanol precipitated and ligated to kinased Bel I linkers.
  • the resultant ligation mixture was digested with Bel I and was electrophoresed through an agarose gel.
  • the 5.8 kb fragment was isolated from the gel and was recircularized by self-ligation.
  • a plasmid having the desired modification was selected and designated pDHFR .
  • Plasmid pDHFR' was transformed into a dAM ⁇ ⁇ L. coli strain and plasmid DNA was prepared.
  • Plasmid pD2' was then generated by cleaving pDHFR' and pSV40 (comprising Bam Hi-digested SV40 DNA cloned into the Bam HI site of pML-1) with Bel I and Bam HI to isolate the 0.2 kb SV40 polyadenylation signal and the 4.9 kb pDHFR' fragment. The 0.2 kb pSV40 fragment and the 4.9 kb pDHFR' fragment were then ligated to construct plasmid pD2 ' . Plasmid pD2' was modified by deleting the
  • Plasmids pD2 / and pML- 1 were digested with Eco RI and Nru I and the fragments were separated by agarose gel electrophoresis. The 1.9 kb pD2 fragment and the 1.8 kb pML-1 fragment were isolated and ligated together. A plasmid having the desired structure was selected and designated pD2.
  • This plasmid was then digested with Eco RI and Bgl II and a 2.8 kb fragment, comprising the 3 ' splice signal, SV40 polyadenylation signal and pML-1 vector sequences, was isolated and designated fragment C.
  • Plasmid pDHFRIII was digested with Sst II, incubated with dCTP and T 4 DNA polymerase, and ligated to kinased Hind III or Kpn I linkers. The resultant plasmids were digested with Hind III or Kpn I, as appropriate, and electrophoresed through agarose. Gel-isolated DNA was then religated and used to transform E_j_ coli RR1. The resultant plasmids were designated pDHFRIII(Hind III) and pDHFRIII(Kpn I).
  • a 700 bp Kpn I-Bgl II fragment (fragment A) was then purified from pDHFRIII(Kpn I) by digestion with Bgl II and Kpn I followed by agarose gel electrophoresis.
  • the SV40 enhancer sequence was inserted into pDHFRIII(Hind III) in the following manner. SV40 DNA was digested with Hind III and the Hind III C SV40 fragment (5089-968 bp) was gel purified and inserted in the Hind III site of pDHFRIII(Hind III).
  • the resultant plasmid, pE2 was then digested with Eco RI and Kpn I, and a 700 bp fragment, containing the Ad5 ori and the SV0 enhancer (designated fragment B) , was isolated.
  • fragments A, B and C were joined in a three-part ligation and the mixture was used to transform IL_ coli RR1. Positive colonies were selected and the vector was designated pD3.
  • Plasmids pD5 and pDll comprising the Ad5 ori, SV40 enhancer, Ad2 major late promoter, Ad2 tripartite leader (Ll-3) , 5' and 3' splice signals, the SV40 polyadenylation signal and pML-1 vector sequences, were constructed to introduce a unique Bam HI site.
  • pDHFRIII was first modified by converting the Pst I site immediately upstream from the DHFR sequence to a Bam HI site by incubating Pst I partially digested pDHFRIII with dCTP in the presence of T 4 DNA polymerase.
  • Plasmid pDl was then generated from pDl' by first cleaving pSV40 (comprising Bam HI digested with SV40 DNA cloned into the Bam HI site of pML-1) with Bel I and Bam HI to isolate the 0.2 kb SV40 polyadenylation signal.
  • Plasmid pDl' was linearized by digestion with Bam HI and the 4.9 kb fragment was isolated. These fragments were then ligated with the SV40 polyadenylation sequence in the late orientation to construct plasmid pDl. Plasmid pDl was modified by deleting the
  • Plasmids pDl and pML- 1 were digested with Eco RI and Nru I and the fragments were separated by agarose gel electrophoresis. The 1.9 kb pDl fragment and the 1.8 kb pML-1 fragment were isolated and ligated together. A plasmid having the desired structure was selected and designated ppDl.
  • This plasmid was then digested with Eco RI and Bgl II and a 2.8 kb fragment, comprising the 3 ' splice signal, SV40 polyadenylation signal and pML-1 vector sequences, was isolated and designated fragment C'.
  • the SV40 enhancer sequence was inserted into pDHFRIII(Hind III) in the following manner.
  • SV40 DNA was digested with Hind III and the Hind III C SV40 fragment (5089-968 bp) was gel purified and inserted in the Hind III site of pDHFRIII(Hind III) by ligation.
  • the ligation mixture was transformed into E ⁇ . coli RR1.
  • Plasmid DNAs prepared from the transfor ants were screened by restriction enzyme analysis. Two plasmids were isolated.
  • One, designated pEl contained the enhancer oriented with the Kpn I site distal to the Ad5 ori and the other, designated pE2, contained the enhancer oriented with the Kpn I site proximal to the Ad5 ori.
  • Plasmid pEl was then digested with Eco RI and Kpn I, and a 700 bp fragment, containing the Ad5 ori and the SV40 enhancer (designated fragment B'), was isolated. Plasmid pE2 was digested with Kpn I and Bgl II to isolate the 0.9 kb fragment (fragment D').
  • Plasmid pDHFRIII(Kpn I) (Example 1) was digested with Kpn I and Bgl II to isolate the 700 bp Kpn I-Bgl II fragment (designated fragment A') and EcoRl and Kpn I to isolate the 0.4 kb fragment comprising the Ad5 ori (fragment E') .
  • fragments A 7 , B' and C were joined in a three-part ligation and fragments C , D and E' were joined in a three-part ligation.
  • the mixtures were then transformed into E ⁇ _ coli RR1.
  • Plasmid DNA was prepared and analyzed by restriction enzyme analysis.
  • a plasmid from the ligation of fragments A" , B" and C was designated pD5 ( Figure 1) .
  • a plasmid from the ligation of fragments C , D' and E' was designated pDll ( Figure 4).
  • Plasmid pBoel360 comprising a polycistronic transcription unit containing a mouse DHFR r cDNA and a CAT gene, was constructed from the precursor plasmids pDHFRI (Berkner and Sharp, Nuc. Acids Res. 12:1925-1941, 1984), pDHFRIII (Berkner and Sharp, Nuc. Acids. Res. 11:841-857, 1985) and pD5CAT.
  • the DHFR r cDNA was constructed from the wild- type DHFR cDNA as described by Boel et al. (FEBS Lett. 219:181-188, 1987) . Briefly, plasmid pDHFRI was digested with Bgl II and Bam HI to isolate the 1050 bp fragment comprising the DHFR cDNA. The Bgl II-Bam HI fragment was joined in a two-part ligation to pEMBLS (Dente et al., Nuc. Acids Res. 11:1645-1655, 1983) which had been linearized by digestion with Bam HI. A plasmid containing the insert in the proper orientation was designated pDHFR/pEMBL8.
  • Single-stranded pDHFR/pEMBL8 DNA was prepared and was subjected to site-directed in vitro mutagenesis using the method of Zoller and Smith (DNA 1:479-488, 1984) and the mutagenic oligonucleotide ZC165 (5' GAG GCC AGG GTC GGT CTC CG 3* * ).
  • Mutagenesis using ZC165 introduced a Leu to Arg mutation at position 22 of the DHFR cDNA resulting in the DHFR r mutant cDNA as described by Simonsen and Levinson (Proc. Natl. Acad. Sci. USA 0:2495-2499, 1983). Positive colonies were identified by colony hybridization with labeled ZC165 and the mutation was confirmed by dideoxy sequencing.
  • Replicative form DNA was prepared from a positive plaque and was digested with Xho II to isolate the fragment comprising the DHFR r cDNA. Plasmid pDHFRI was digested with Bgl II and Bam HI to isolate the vector-containing sequences. The Xho II pDHFRI fragment was joined in a two-part ligation to the DHFR r cDNA fragment. A plasmid containing the DHFR r cDNA in the proper orientation was designated pDHFR r I ( Figure 1) .
  • Plasmid pD5CAT was a progenitor plasmid for the CAT-DHFR r polycistronic transcription unit and was constructed from the progenitor plasmid pD5.
  • a chloramphenicol transacetylase (CAT) gene was inserted into the Bam HI site of pD5 to construct plasmid pD5CAT as follows. Plasmid pD5 was linearized by digestion with Bam HI. The CAT cDNA was provided as a Bam Hl-Xho II fragment and was joined with the linearized pD5 in a two-part ligation. A plasmid containing the CAT cDNA fragment in the correct orientation was designated pD5CAT ( Figure 1) .
  • a polycistronic transcription unit was constructed in pD5CAT, as shown in Figure 1. Plasmid pDHFR r I was digested with Fnu 4HI and the adhesive ends were blunted by treatment with T4 DNA polymerase and the four deoxyribonucleotide triphosphates. Kinased Bam HI linkers were added to the blunted fragments and the 1inkered fragments were digested with Bam HI and Nco I. A 0.62 kb fragment, comprising a portion of the DHFR r cDNA, was isolated by gel electrophoresis and electroelution.
  • Plasmid pDHFR r I was also digested with Xba I and partially digested with Nco I to isolated the fragment comprising the 3 end of the DHFR r cDNA, the SV40 polyadenylation signal and 276 bp of pBR322 vector sequence.
  • Plasmid pD5CAT was digested with Xba I and partially digested with Bam HI to remove the SV40 polyadenylation signal and 276 bp of pML vector sequences.
  • the Xba I-Bam HI vector and CAT gene fragment of pD5CAT was joined with the Nco I-Xba I fragment and the Bam HI-Nco I fragment in a three part ligation.
  • the resulting plasmid was designated pD5CAT- DHFR r .
  • Figure 1 diagrams the modification of plasmid pD5CAT-DHFR r to change the Bam HI site 3* * to the SV40 polyadenylation signal to a Cla I site.
  • Plasmid pD5CAT- DHFR r was digested with Xba I and Sst I to isolate the 0.9 kb fragment comprising part of the DHFR r cDNA, the SV40 polyadenylation signal and pML-1 vector sequences.
  • the 0.9 kb fragment was joined to Xba I-Sst I linearized pUC13 by ligation.
  • the resultant plasmid designated pBoel360a
  • pBoel360a was digested with Bam HI and the adhesive ends were filled in by treatment with DNA polymerase I (Klenow fragment) and the four deoxyribonucleotide triphosphates.
  • the DNA was recircularized by ligation and the resultant plasmid, which contained a Cla I site in place of the Bam HI site of pBoel360a, was designated pBoel360b.
  • Plasmid pBoel360b was then digested with Xba I and Sst I and the 0.9 kb insert was isolated.
  • Plasmid pD5CAT-DHFR r was digested with Xba I and Sst I to remove the 0.9 kb fragment comprising the 3 ' portion of the DHFR r cDNA, the SV40 polyadenylation signal and the pML vector sequences.
  • the Xba I-Sst I vector-containing fragment from pD5CAT-DHFR r was joined with the 0.9 kb Xba I-Sst I fragment from pBoel360b.
  • the resultant plasmid was designated pBoel360 ( Figure 1) .
  • a recombinant adenovirus vector was generated by cotransfecting 293 cells with pBoel360 and incomplete Ad5 viral DNA essentially as described by Stow (J. Virol. 17:171-180, 1981) and Berkner and Sharp (Nuc. Acids Res. 11:6003-6020, 1983).
  • An Xba I site was substituted for the Bgl II site at u 9.4 of Ad5 and the Xba I 9.4-100 mu fragment was prepared. This fragment was ligated to Xba I-digested pBoel360, and 10 mg of DNA was used to transfeet the cells by the calcium phosphate method.
  • Recombinant virus was recovered and designated Ad5(CAT-DHFR) .
  • hGM-CSF human granulocyte-macrophage colony- stimulating factor coding sequence
  • RNA prepared essentially as described by Chirgwin et al. (Biochemistry 18:5294-5299, 1979), was used as a template in the preparation of a lambda gtll cDNA library using an adaptation of the method described by Gubler and Hoffman (Gene 2_5:263-269, 1983).
  • a complete cDNA clone comprising a portion of the Ll-3 fused to the hGM-CSF coding sequence was isolated from the lambda phage by digestion with Eco RI and ligated into the unique Eco RI site of pGEM-1 (Promega Biotec, Madison, WI) .
  • the resultant plasmid, designated pGEMcGM.Eco.1100 contained two copies of the hGM-CSF cDNA oriented in tandem in the pGEM-1 vector ( Figure 2) .
  • the Ll-3 leader sequence used in the intercistronic region of the polycistronic transcription unit was derived from plasmids pGEMcGM.Eco.1100 (Example 4) and plasmid D S /PUC, comprising the Ad5 ori, Ad2 major late promoter (MLP) , Ad2 Ll-3 and its accompanying 5' splice signal, immunoglobulin 3 ' splice site, a DHFR cDNA, the SV40 polyadenylation signal and pUC13 vector sequences.
  • plasmid pGEMcGM.Eco.1100 was digested with Bel I to isolate the 0.8 kb fragment comprising the CSF cDNA fused to the Ll- 3 leader sequence.
  • Oligonucleotides ZC582 (5' AAT TCC CGG G 3 * ") and ZC583 (5' GTA CCC CGG G 3') were kinased and annealed using conditions generally described by Maniatis (ed. Molecular Cloning A Laboratory Manual, Cold Spring Harbor, NY, 1982) .
  • the kinased, annealed oligo-nucleotides formed a Bam HI-Eco RI adaptor which was joined to the 0.8 kb pGEMcGM.Eco.1100 fragment by ligation.
  • the ligation mixture was digested with Eco RI to isolate the 0.2 kb fragment comprising the Ll-3 leader sequence.
  • Plasmid pUC13 was linearized by digestion with Eco RI and was subsequently treated with calf intestinal phosphatase to prevent recircularization.
  • the 0.2 kb Ll-3 fragment was joined to the linearized pUC13 by ligation.
  • the resultant plasmid was designated CSF Ll-3 #12 (#265) ( Figure 2) .
  • Plasmid pD s /PUC is derived from plasmid pDHFRIII which has been disclosed by Berkner and Sharp (ibid. , 1985) . Plasmid pDHFRIII was modified to place a unique Kpn I site at the Sst II site between the Ad5 ori and the Ad2 MLP. Plasmid pDHFRIII was linearized by digestion with Sst II and the linear fragment was blunt-ended by treatment with T4 DNA polymerase and the appropriate nucleotides. The linear fragment was joined with kinased Kpn I linkers.
  • Plasmid pDHFRIII/Sst->Kpn I was digested with Eco RI and Xba I to isolate the 2.4 kb fragment comprising the Ad5 ori, Ad2 MLP, 5' splice signal, 3 ' splice signal, a DHFR cDNA, SV40 polyadenylation signal and approximately 300 bp of pBR322 vector sequences.
  • the 2.4 kb fragment was ligated with pUC13 which had been linearized by digestion with Eco RI and Xba I.
  • the resultant plasmid was designated pD s /PUC.
  • plasmid pD s /PUC was digested with Eco RI and Pst I to isolate the 1.1 kb fragment comprising the Ad5 ori, Ad2 MLP and Ll-3, and 5' and 3 ' splice signals.
  • the 1.1 kb fragment was digested with Hha I to isolate the 500 bp fragment comprising the Ll-3 and associated 5' and 3 ' splice signals.
  • the 500 bp fragment was subsequently treated with T4 DNA polymerase to blunt the adhesive ends.
  • the blunt-ended fragment was ligated to kinased Bam HI linkers. Excess linkers were removed by digestion with Bam HI and the linkered fragment was inserted into the Bam HI site of pUC13.
  • Ll-3 Bam-Pst (#301) ( Figure 2) .
  • Figure 2 shows the construction of plasmid pTP(#323).
  • Plasmid CSF Ll-3 #12 (#265) was digested with Xho I and Nde I to isolate the 2.5 kb fragment comprising the 3' portion of the Ll-3 and the pUC13s vector sequences.
  • Plasmid Ll-3 Bam-Pst (#301) was digested with Bam HI and Xho I to isolate the 0.17 kb fragment comprising the 5' portion of the Ll-3.
  • the E. coli vector pUC13 was digested with Bam HI and Nde I to isolate the 200 bp vector fragment.
  • the 0.17 kb Ll-3 fragment from Ll-3 Bam Hl-Pst I (#301) was joined with the 2.5 kb fragment from CSF Ll-3 #12 (#265) and the 200 bp fragment of pUC13 in a three part ligation.
  • the resultant plasmid was designated pTP (#323) ( Figure 2) .
  • Plasmid pTP (#323) was digested with Bam HI to isolate the 0.2 kb Ll-3 fragment.
  • Plasmid pBoel360 (also known as Cla I (#221) and described in Example 2) was subjected to a partial digestion with Bam HI to linearize the plasmid.
  • the linearized pBoel360 was joined with the 0.2 kb Bam HI fragment of pTP (#323) in a two part ligation.
  • the ligation mixture was transformed into E ⁇ . coli HB101.
  • Plasmid DNA was isolated from the transformants and analyzed by restriction enzyme digestion to verify the correct orientation of the component fragments.
  • a plasmid containing the Ll-3 fragment inserted in the correct orientation into the intercistronic region between CAT and DHFR was designated pTP/Cla (#431) ( Figure 2) .
  • Plasmid pTP/Cla was used to generate the adenovirus vector Ad5(TPCla) by transfection of 293 cells essentially as described in Example 3. 33
  • Example 6 Effect of the intercistronic leader on the level of expression of DHFR
  • the level of DHFR protein was measured in cells infected with Ad5- (CAT-DHFR) or Ad5(TPCla) recombinant virus by Western transfer assay.
  • Sub-confluent 293 cells were infected with Ad5(CAT-DHFR) or Ad5(TPCla) recombinant virus.
  • the infected cells were incubated and harvested when the cells showed considerable cytopathic effects.
  • the harvested cells were pelleted by centrifugation to remove the spent media. Excess media was removed by one rinse with phosphate buffered saline (PBS; Sigma, St. Louis, MO) .
  • the cells were resuspended in 0.25 M Tris HC1, pH 7.4.
  • the cell suspensions were frozen and thawed three times to lyse the cells.
  • Cell debris was removed by centrifugation and 50 ul of the supernatant was mixed with 50 ul 2x Sample Buffer (Table 1) and electrophoresed on a 15% acrylamide gel.
  • the proteins were also transferred to a nitrocellulose filter using the method described by Towbin et al. (Proc. Natl. Acad. Sci. USA 76:4350-4353, 1979) .
  • the nitrocellulose filter was immersed in Western Buffer A (Table 1) for 1 hour at room temperature.
  • the buffer was removed and the filter was probed with an anti-DHFR antibody diluted in Western Buffer A for 1 hour at room temperature.
  • the antibody solution was removed and excess antibody was removed from the filter by three washes with Western Buffer A.
  • the protein bound by the antibody was visualized by a 1 hour, room temperature incubation with 1251 -labelled Protein A diluted in Western Buffer A.
  • the labelled Protein A solution was discarded and excess label was removed by three washes with Western Buffer A.
  • the labelled filter was exposed to X-ray film for four hours at -80°C with an intensifying screen.
  • the results show that DHFR r protein produced by cells infected with Ad5(TPCla) recombinant virus was present at high levels, but was not detected in cells infected with Ad5(CAT- DHFR) recombinant virus.
  • BHK cells were transfected with pD5CAT-DHFR r or a control plasmid containing a monocistronic DHFR expression unit.
  • the mRNA produced by the transfectants was hybridized to a 32 P-labeled antisense DNA probe (Figure 3b) and the mixture was digested with ⁇ l nuclease to remove the unhybridized probe.
  • Analysis of the products indicated that pD5CAT-DHFR r directed the expression of dicistronic mRNA (lanes 1 and 2, arrows), whereas the monocistronic plasmid directed the production of a smaller mRNA.
  • the doublet observed with the dicistronic message is ' due to splicing in a portion of the transcripts as shown in Figure 3b.
  • the top band in lanes 1 and 2 represents undigested probe DNA.
  • mRNA produced from cells transfected with a polycistronic expression unit containing an intercistronic tripartite leader was analyzed by Northern blot (Thomas, Proc. Natl. Acad. Sci. USA 22:5201, 1980). Results indicated that mRNA of the size predicted for the dicistronic message was produced.
  • a tricistronic transcription unit comprising a factor IX cDNA, CAT gene and DHFR r cDNA, was constructed from the factor IX cDNA and pBoel360 as shown in Figure 4.
  • Plasmid pBoel360 (Example 3) was partially digested with Bam HI to linearize the plasmid. The adhesive ends were treated with calf alkaline phosphatase, essentially as described by Maniatis et al. (ibid.), to prevent self-ligation.
  • Plasmid pF9pUC was digested with Bam HI to isolate the 1.4 kb factor IX cDNA fragment which was joined with the linearized pBoel360 by ligation. The ligation mixture was transformed into E ⁇ . coli strain HB101. Plasmid DNA was prepared and was screened by restriction enzyme digestion. A plasmid with the factor IX cDNA fragment inserted in the proper orientation and 5' to the CAT cDNA sequence was designated pF9/Cla ( Figure 4) .
  • the tripartite leader sequence present in plasmid pTP(#323) was inserted between the translation termination codon of the factor IX cDNA and the translation initiation codon of the CAT cDNA as follows. Plasmid pF9/Cla was digested with Bam HI and Pst I to isolate the fragment comprising the 5' coding sequence of the factor IX cDNA (1.4 kb) . Plasmid pTP (#323) (Example 5) was linearized by partial digestion with Bam HI and treated with phosphatase. The linearized pTP was joined with the factor IX fragment by means of a Pst I Bam HI adapter. The adapter, constructed from oligonucleotides
  • ZC2029 (5' GAT CTC ACC GTC TGC A 3 ' ) and ZC2030 (5' GAC GGT GA 3') destroyed the Bam HI site but preserved the Pst I site on the factor IX fragment.
  • the resultant plasmid was designated IX[TP] (#515) .
  • Plasmid pF9/Cla was digested with Ava I and Hind III, and the 4.9 kb fragment containing the pML-1 sequence was recovered. Plasmid pF9/Cla was also digested with Hind III and Ssp I, and the 1.5 kb fragment containing the MLP, Ll-3 and 5' factor IX sequences was recovered.
  • the two pF9/Cla-derived fragments were then joined to the factor IX-L1-3 Ssp I-Ava I fragment from plasmid IX[TP] .
  • the resultant plasmid was designated pTP/F9/Cla ( Figure 4) .
  • Plasmids pTP/F9/Cla and pF9/Cla were transfected into BHK cells and transient expression levels of chloramphenicol acetyl transferase were measured.
  • CAT expression in pTP/F9/Cla transfectants was approximately 20-fold higher than in pF9/Cla transfectants.
  • Plasmid pDX was constructed from plasmid pD3', a vector identical to pD3 except that the SV40 polyadenylation signal is in the late orientation.
  • pD3' contains a Bam HI site as the site of gene insertion.
  • Bel I-cleaved pD3 (Example 1) was ligated with kinased Eco RI-Bcl I adaptors (constructed from oligonucleotides ZC525, 5' GGAATTCT 3' ; and ZC526, 5' GATCAGAATTCC 3'), in order to generate an Eco RI site as the position for inserting a coding sequence into the expression vector. Positive colonies were identified by restriction analysis, and plasmid DNA prepared from a positively identified colony was used to isolate a 2.3 kb Xho I-Pst I fragment containing the modified restriction site.
  • pD3 and pD3 fragments were incubated together with T4 DNA ligase, transformed into E ⁇ coli HB101 and positive colonies were identified by restriction analysis.
  • a plasmid containing the desired expression vector was designated pDX ( Figure 5) .
  • An expression vector comprising the Ad5 ori, SV40 enhancer, Ad2 major late promoter and tripartite leader, 5' and 3' splice signals, a factor VII cDNA and the SV40 polyadenylation signal is generated from plasmids pDX, pDll, and pFVII(565+2463)/pDX (ATCC Accession no. 40205) .
  • the factor VII cDNA present in pFVII(565+2463)/pDX was modified to remove the 3' untranslated region.
  • Plasmid pFVII(565+2463)/pDX was digested with Eco RI to isolate the 2.4 kb factor VII cDNA fragment.
  • the Eco RI fragment was partially digested with Mbo II to isolate the 1.4 kb Eco RI-Mbo II fragment comprising the factor VII coding sequence.
  • the 1.4 kb fragment was ligated with the kinased adapter and pUC13 which had been linearized by digestion with Eco RI and Bam HI.
  • the resultant plasmid, pUCFVII was digested with Eco RI and Bam HI to isolate the 1.4 kb fragment (fragment a) .
  • Plasmid pDX is digested with Eco RI and Xba I to isolate the 4.0 kb fragment comprising the Ad5 ori, SV40 enhancer, Ad2 major late promoter and tripartite leader, 5* * and 3 ' splice signals and pBR322 vector sequences (fragment b) .
  • Plasmid pDll (Example 2) is digested with Bam HI and Xba I to isolate the 0.5 kb fragment comprising the SV40 polyadenylation signal and pML-1 vector sequences (fragment c) .
  • fragment c To construct pFVII fragments a, b, and c are joined in a three-part ligation.
  • An expression vector was constructed which comprised the Ad5 ori, the SV40 enhancer, the Ad2 major late promoter and tripartite leader, 5' and 3' splice signals, a BiP cDNA, and the SV40 polyadenylation signal was constructed from plasmids pDll (Example 2) , pBiP(pUC12) and pDX ( Figure 5).
  • BiP cDNA was obtained as a 2.4 kb Eco RI fragment in pUC12 (described by Munro and Pelham, Cell 46:291-300, 1986) and was designated BiP(pUC12) .
  • the BiP cDNA was subcloned into the expression unit present in pDll as follows.
  • the BiP cDNA was isolated from the pUC12 vector sequences as two fragments.
  • BiP(pUC12) was digested with Bam HI and Kpn I to isolate the 1.6 kb fragment and with Kpn I and Eco RI to isolate the 0.86 kb fragment.
  • Plasmid pDX was digested with Eco RI and Xba I to isolate the 0.5 kb fragment comprising the SV40 polyadenylation signal and pML-1 vector sequences.
  • Plasmid pDll was digested with Bam HI and Xba I to isolate the 4.0 kb fragment comprising the Ad5 ori, SV40 enhancer, Ad2 major late promoter and tripartite leader and 5' and 3 ' splice signals and pML-1 vector sequences.
  • Plasmid pDll-BIP was generated by the ligation of the four fragments described above.
  • This plasmid comprised the Ad5 ori, SV40 enhancer, Ad2 major late promoter and tripartite leader and 5' and 3 ' splice signals, BiP cDNA, SV40 polyadenylation signal and pML-1 vector sequences.
  • Plasmid pFVII-TP-BIP A dicistronic transcription unit containing the factor VII and BiP cDNAs is constructed from plasmids pFVII, pDll-BIP and pTP as shown in Figure 5. Plasmid pDll-BIP is digested with Eco RI and
  • the .5 kb fragment is joined with an Eco RV-Xba I synthetic adapter and pUC13 which has been linearized by digestion with Eco RI and Xba I.
  • the resultant plasmid is linearized by digestion with Nae I which cleaves the BiP fragment 5 bp 5 ** to the translation initiation codon.
  • the linearized plasmid is recircularized by ligation with synthetic Bam HI linkers.
  • the resultant plasmid is linearized by digestion with Bam HI and joined by ligation with the 0.2 kb Bam HI fragment, comprising the tripartite leader, obtained from Bam HI digested pTP (Example 5) .
  • the resultant plasmid is partially digested with Bam HI and completely digested with Eco RV to isolate the 0.7 kb fragment comprising the tripartite leader and 5' BiP coding sequence.
  • Plasmid pFVII is digested with Hind III and Bam HI to isolate the 2.1 kb fragment comprising the Ad2 major late promoter and tripartite leader, 5' and 3 ' splice signals and the factor VII cDNA.
  • Plasmid pDll- BIP is digested with Hind III and Eco RV to isolate the 5.5 kb fragment comprising the SV40 enhancer, Ad5 ori, pML-1 vector sequences, SV40 polyadenylation signal and the 3' 1.9 kb of the Bip cDNA.
  • the three fragments (0.7 kb tripartite leader and 5' BiP, 2.1 kb pFVII, and 5.5 kb pDll-BIP) are joined in a three-part ligation.
  • the resultant plasmid is designated pFVII-TP-BIP.

Landscapes

  • Genetics & Genomics (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

L'invention concerne des procédés d'amélioration de l'expression de protéines dans des cellules cultivées dérivées d'un organisme multicellulaire. Les procédés comprennent l'introduction dans la cellule hôte d'une unité de transcription polycistronique de formule P-C1-(HEL-Cn)m. L'unité de transcription polycistronique peut comprendre en outre un leader positionné en aval du promoteur et en amont de C1.
PCT/US1989/003228 1988-07-29 1989-07-26 Translation de haut rendement de messages polycistroniques dans des cellules eucariotiques WO1990001550A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22617388A 1988-07-29 1988-07-29
US226,173 1988-07-29

Publications (1)

Publication Number Publication Date
WO1990001550A1 true WO1990001550A1 (fr) 1990-02-22

Family

ID=22847870

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1989/003228 WO1990001550A1 (fr) 1988-07-29 1989-07-26 Translation de haut rendement de messages polycistroniques dans des cellules eucariotiques

Country Status (4)

Country Link
EP (1) EP0426744A1 (fr)
JP (1) JPH04500004A (fr)
AU (1) AU4036389A (fr)
WO (1) WO1990001550A1 (fr)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994005786A1 (fr) * 1992-08-27 1994-03-17 Beiersdorf Ag Production de pdgf-ab heterodimeres a l'aide d'un systeme vectoriel bicistronique dans des cellules mammiferes
WO1994005785A1 (fr) * 1992-08-27 1994-03-17 Beiersdorf Ag Unites multicistroniques d'expression et leur utilisation
EP0598029A1 (fr) * 1991-08-07 1994-05-25 ANDERSON, W., French Vecteurs retroviraux contenant des sites internes d'entree de ribosome
WO1996008593A1 (fr) * 1994-09-16 1996-03-21 Huyck Licensco, Inc. Toile pour formation de papier
WO1996008574A1 (fr) * 1994-09-13 1996-03-21 Transgene S.A. Nouvel implant et nouveau vecteur pour le traitement des maladies acquises
EP0706319A1 (fr) * 1993-01-20 1996-04-17 Biotransplant, Inc Vecteurs retroviraux capables d'exprimer des proteines multimeres a partir de sites multiples d'initiation de traduction
EP0711835A1 (fr) * 1994-11-14 1996-05-15 Immuno Ag Sélection et expression des protéins hétérologues utilisant un système amplification-sélection
WO1996027676A2 (fr) * 1995-03-03 1996-09-12 Q.B.I. Enterprises Ltd. Procede et moyens de production de produits genetiques, nouveaux vecteurs d'adn recombinant s'y rapportant et necessaires en vue de leur utilisation
WO1996033272A1 (fr) * 1995-04-18 1996-10-24 KLINIKUM DER ALBERT-LUDWIGS-UNIVERSITäT FREIBURG Vecteurs de transfection de cellules eucaryotes, leur utilisation et cellules cibles transfectees a l'aide desdits vecteurs
US5648235A (en) * 1992-07-03 1997-07-15 Q.B.I. Enterprises Ltd. Method and means for the production of gene products, novel recombinant DNA vectors therefor and kits employing them
WO2001028994A2 (fr) * 1999-10-15 2001-04-26 The Mclean Hospital Corporation Domaines multimerises d'activateurs dbh
AU780164B2 (en) * 1994-09-13 2005-03-03 Transgene S.A. Novel implant and novel vector for the treatment of acquired diseases
US7037715B2 (en) 1999-10-15 2006-05-02 The Mclean Hospital Multimerized DBH enhancer domains
US7585962B2 (en) 2001-10-19 2009-09-08 The Mclean Hospital Corporation Multimerized enhancer domains for cell-specific expression

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5990091A (en) * 1997-03-12 1999-11-23 Virogenetics Corporation Vectors having enhanced expression, and methods of making and uses thereof
EP2848687B1 (fr) 2012-04-27 2017-09-13 JCR Pharmaceuticals Co., Ltd. Nouveau vecteur d'expression

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0117058A2 (fr) * 1983-01-19 1984-08-29 Genentech, Inc. Procédés de production de protéines matures dans des cellules hôtes de vertébrés
EP0154576A1 (fr) * 1984-02-06 1985-09-11 INTERFERON SCIENCES, INC a Delaware Corporation Séquences d'acides nucléiques hybrides ayant des gènes disposés en tandem
EP0219214A1 (fr) * 1985-08-30 1987-04-22 Kabushiki Kaisha Yakult Honsha Vecteur chimérique de plasmide
WO1987002707A1 (fr) * 1985-11-05 1987-05-07 Genetics Institute, Inc. Vecteurs amplifiables par multiplication pour expression d'adn hexogene en grande quantite
WO1988005466A2 (fr) * 1987-01-15 1988-07-28 Codon Vecteurs d'expression eukaryotique de genes en tandem

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0117058A2 (fr) * 1983-01-19 1984-08-29 Genentech, Inc. Procédés de production de protéines matures dans des cellules hôtes de vertébrés
EP0154576A1 (fr) * 1984-02-06 1985-09-11 INTERFERON SCIENCES, INC a Delaware Corporation Séquences d'acides nucléiques hybrides ayant des gènes disposés en tandem
EP0219214A1 (fr) * 1985-08-30 1987-04-22 Kabushiki Kaisha Yakult Honsha Vecteur chimérique de plasmide
WO1987002707A1 (fr) * 1985-11-05 1987-05-07 Genetics Institute, Inc. Vecteurs amplifiables par multiplication pour expression d'adn hexogene en grande quantite
WO1988005466A2 (fr) * 1987-01-15 1988-07-28 Codon Vecteurs d'expression eukaryotique de genes en tandem

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, Vol. 107, No. 11, 14 September 1987, (Columbus, Ohio, US), E. BOEL et al.: "Expression of Human Pancreatic Polypeptide Precursors from a Dicistronic mRNA in Mammalian Cells", see page 206* Abstract 91240v & FEBS Lett. 1987, 219(1), 181-8* *
CHEMICAL ABSTRACTS, Vol. 107, No. 21, 23 November 1987, (Columbus, Ohio, US), V.V. KRAVCHENKO et al.: "Construction and Properties of Artificial Polycistrons Containing Truncated E. Coli Tryptophan Operon Gene and M13 Coat Protein Gene", see page 206* Abstract 192226a & Bioorg. Khim. 1987, 13(9), 1176-85* *
CHEMICAL ABSTRACTS, Vol. 108, No. 5, 1 February 1988, (Columbus, Ohio, US), see page 504* Abstract 36330v & JP-A-6291199 (Fujisawa Pharmaceutical Co. Ltd) 25 April 1987* *
CHEMICAL ABSTRACTS, Vol. 109, No. 21, 21 November 1988, (Columbus, Ohio, US), K.L. BERKNER: "Development of Adenovirus Vectors for the Expression of Heterologous Genes", see page 155* Abstract 184334k & BioTechniques 1988, 6(7), 616-18, 620-4, 626,628-9* *
Gene, Vol. 34, 1985, Elsevier Science Publishers S. JOHNSTON et al.: "High-Level Expression of M13 Gene II Protein from an Inducible Polycistronic Messenger DNA", pages 137-145 *
Nucleic Acids Research, Vol. 13, No. 3, 1985 K.L. BERKNER et al.: "Effect of the Triparite Leader on Synthesis of a Non-Viral Protein in an Adenovirus 5 Recombinant", pages 841-857 *
Proc. Natl. Acad. Sci, USA, Vol. 82, February 1985 (US) R.J. KAUFMAN: "Identification of the Components Necessary for Adenovirus Translational Control and their Utilization in cDNA Expression Vectors" pages 689-693 *

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0598029A4 (en) * 1991-08-07 1996-04-17 W French Anderson Retroviral vectors containing internal ribosome entry sites.
EP0598029A1 (fr) * 1991-08-07 1994-05-25 ANDERSON, W., French Vecteurs retroviraux contenant des sites internes d'entree de ribosome
US5648235A (en) * 1992-07-03 1997-07-15 Q.B.I. Enterprises Ltd. Method and means for the production of gene products, novel recombinant DNA vectors therefor and kits employing them
US6060273A (en) * 1992-08-27 2000-05-09 Beiersdorf Ag Multicistronic expression units and their use
US5935819A (en) * 1992-08-27 1999-08-10 Eichner; Wolfram Process for producing a pharmaceutical preparation of PDGF-AB
WO1994005786A1 (fr) * 1992-08-27 1994-03-17 Beiersdorf Ag Production de pdgf-ab heterodimeres a l'aide d'un systeme vectoriel bicistronique dans des cellules mammiferes
WO1994005785A1 (fr) * 1992-08-27 1994-03-17 Beiersdorf Ag Unites multicistroniques d'expression et leur utilisation
US5665567A (en) * 1992-08-27 1997-09-09 Beiersdorf Ag Preparation of heterodimeric PDGF-AB using a bicistronic vector system in mammalian cells
EP0706319A1 (fr) * 1993-01-20 1996-04-17 Biotransplant, Inc Vecteurs retroviraux capables d'exprimer des proteines multimeres a partir de sites multiples d'initiation de traduction
EP0706319A4 (fr) * 1993-01-20 1998-04-22 Biotransplant Inc Vecteurs retroviraux capables d'exprimer des proteines multimeres a partir de sites multiples d'initiation de traduction
US6960469B2 (en) 1994-09-13 2005-11-01 Transgene S.A. Adenoviral vectors encoding an antibody fused to a CD4 extracellular domain
AU780164B2 (en) * 1994-09-13 2005-03-03 Transgene S.A. Novel implant and novel vector for the treatment of acquired diseases
WO1996008574A1 (fr) * 1994-09-13 1996-03-21 Transgene S.A. Nouvel implant et nouveau vecteur pour le traitement des maladies acquises
WO1996008593A1 (fr) * 1994-09-16 1996-03-21 Huyck Licensco, Inc. Toile pour formation de papier
US6114146A (en) * 1994-11-14 2000-09-05 Baxter Aktiengesellschaft Expression plasmid, a fusion protein, a transfected eukaryotic cell line, a method of producing foreign proteins, a foreign protein preparation as well as a pharmaceutical composition
EP0711835A1 (fr) * 1994-11-14 1996-05-15 Immuno Ag Sélection et expression des protéins hétérologues utilisant un système amplification-sélection
WO1996027676A3 (fr) * 1995-03-03 1996-10-31 Q B I Enterprises Ltd Procede et moyens de production de produits genetiques, nouveaux vecteurs d'adn recombinant s'y rapportant et necessaires en vue de leur utilisation
WO1996027676A2 (fr) * 1995-03-03 1996-09-12 Q.B.I. Enterprises Ltd. Procede et moyens de production de produits genetiques, nouveaux vecteurs d'adn recombinant s'y rapportant et necessaires en vue de leur utilisation
WO1996033272A1 (fr) * 1995-04-18 1996-10-24 KLINIKUM DER ALBERT-LUDWIGS-UNIVERSITäT FREIBURG Vecteurs de transfection de cellules eucaryotes, leur utilisation et cellules cibles transfectees a l'aide desdits vecteurs
WO2001028994A2 (fr) * 1999-10-15 2001-04-26 The Mclean Hospital Corporation Domaines multimerises d'activateurs dbh
WO2001028994A3 (fr) * 1999-10-15 2001-09-13 Mclean Hospital Corp Domaines multimerises d'activateurs dbh
US7037715B2 (en) 1999-10-15 2006-05-02 The Mclean Hospital Multimerized DBH enhancer domains
US7585962B2 (en) 2001-10-19 2009-09-08 The Mclean Hospital Corporation Multimerized enhancer domains for cell-specific expression

Also Published As

Publication number Publication date
JPH04500004A (ja) 1992-01-09
AU4036389A (en) 1990-03-05
EP0426744A1 (fr) 1991-05-15

Similar Documents

Publication Publication Date Title
JP3148121B2 (ja) 安定化配列を有するベクターおよび真核宿主細胞
EP0309237B1 (fr) Système d'expression transitoire pour la production de protéine recombinante
WO1990001550A1 (fr) Translation de haut rendement de messages polycistroniques dans des cellules eucariotiques
CA1301675C (fr) Construction d'un vecteur d'expression polycistronique
AU611088B2 (en) Human erythropoietin gene: high level expression in stably transfected mammalian cells
CA1268436A (fr) Production amelioree de matieres proteinacees dans les cellules eucaryotes
JP2505268B2 (ja) 組換えｄｎａ発現ベクタ―
JP3073009B2 (ja) 組換えｄｎａ法及びそこに使用するベクター
JPH0884588A (ja) ヘテロポリマー系蛋白質
Klessig et al. Introduction, stable integration, and controlled expression of a chimeric adenovirus gene whose product is toxic to the recipient human cell
AU660671B2 (en) Methods for selection of recombinant host cells expressing high levels of a desired protein
US4965196A (en) Polycistronic expression vector construction
US5665578A (en) Vector and method for achieving high level of expression in eukaryotic cells
JP2693361B2 (ja) 組織プラスミノーゲン活性化因子の生産方法
Kern et al. Common regulatory elements control gene expression from polyoma early and late promoters in cells transformed by chimeric plasmids
US5747308A (en) Recombinant DNA method
US5149635A (en) Messenger RNA stabilization in animal cells
EP0368926A1 (fr) Cellules transfectees contenant des plasmides comportant des genes orientes dans des directions opposees et leur procede d'obtention
EP0282512B1 (fr) Stabilisation de l'arn messager dans des cellules animales
AU602664B2 (en) DNA sequence containing the DNA sequence coding for human tissue plasminogen activator originating from human normal cells, recombinant DNA incorporating the DNA sequence, host cells transformed with the recombinant DNA, and process for producing human tissue plasminogen activator by use of the host cells
IE66340B1 (en) Cell culture methods for producing activated protein C
RU2079553C1 (ru) Способ получения эукариотического полипептида
WO1988005466A2 (fr) Vecteurs d'expression eukaryotique de genes en tandem
NO845186L (no) Vektorsystem for innfoering av heterolog dna i eykaryotiske celler.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU FI JP NO

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 1989908929

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1989908929

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1989908929

Country of ref document: EP